Thanks for your interest in REACH!
Please complete the form below to get our quarterly email newsletter on:

  • Prioritization considerations for rare disease opportunities
  • Assessment and forecasting for rare disease markets
  • Rare disease clinical trial design
  • Considerations for cell and gene therapy drug development
  • Other related topics

About REACH

Danielle Drayton, PhD
Danielle Drayton, PhD

MEET OUR FOUNDER

Danielle is a seasoned business leader, pharmaceutical market researcher, and PhD-trained immunologist. In her 14-year career at Decision Resources Group (now part of Clarivate), she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies shaping new product planning, business development, commercial strategy, and lifecycle management decisions. Prior to a career in business, Danielle honed her scientific skills and expertise at the Yale and Harvard medical schools.

Danielle’s years as a senior researcher and executive in the Life Sciences industry led to the realization that while rare disease drug development was growing, market research solutions for rare diseases were not. REACH was founded to address a key need: rare disease market insights delivered in an easy-to-consume format, quickly!

Join our team